Xencor

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Xencor reports strong earnings, focuses on innovative pipeline strategies

Xencor's strong financial performance and promising pipeline programs position it well for growth
Unique mechanisms and designs offer competitive advantages in oncology and autoimmune disease treatments
Challenges like revenue expectations and validation requirements are being addressed strategically
Opportunities for collaborations and program optimizations pave the way for future success

Xencor advances internal portfolio with strategic focus on impactful targets

Xencor's Q1 2023 Earnings Call highlighted progress in their internal development portfolio, welcoming a new Chief Development Officer and emphasizing innovative therapeutic formats.
While facing challenges in data updates and program differentiation, the company's strategic focus on impactful targets and early clinical development positions them for future success.
Opportunities lie in expanding therapeutic programs, leveraging royalties, and exploring new avenues for growth, signaling a promising trajectory for Xencor in the biopharmaceutical landscape.

Xencor reports robust Q2 earnings and pipeline advancements

Xencor's Q2 2023 earnings call showcased strong performance in royalties and collaborations
The company's diverse pipeline and focus on safety and selectivity present opportunities
Challenges include addressing safety concerns and finalizing regimen for advancement
Overall, Xencor remains optimistic about future updates and pipeline progress

Xencor reports robust Q3 earnings, advances novel oncology therapeutics

Xencor's Q3 earnings call highlighted a strong financial performance, strategic pipeline adjustments, and progress in developing novel antibody-based therapeutics for oncology. The company is focused on maintaining asset potential through royalty deals and advancing internal pipeline candidates targeting solid tumors.

Xencor reports robust clinical data for vudalimab in prostate cancer

Xencor's Q4 earnings call showcased strong clinical data for vudalimab in prostate cancer, highlighting its efficacy and safety profile. The company's strategic focus on T-cell engagers and XmAb bispecific technology positions it well for future growth and innovation in solid tumor targeting.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Xencor (XNCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Xencor (XNCR) Upgraded to Strong Buy: Here's Why

Johnson & Johnson

Johnson & Johnson's (NYSE: JNJ) Janssen unit has inked a licensing deal worth $100 million in upfront cash and $25 million in equity for global licensing rights with Xencor Inc (NASDAQ: XNCR). The agreement covers Xencor's CD20/CD3 bispecific antibody plamotamab currently in Phase 1 testing against B cell malignancies.

JNJ, Xencor Sign $1.3B Licensing Deal For B-Cell Malignancies-Targeted Bispecific Antibody

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced an exclusive collaboration and worldwide license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop and commercialize plamotamab and novel XmAb® B-cell targeting bispecific antibodies that are desig

Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced five poster presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, being held in Washington, D.C., and virtually November 10-14, 2021. The presentations will include updated clinical results from expansion cohorts in the Phase 1 study o

Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. ET / 1:00 p.m. PT. A live webcast will be available under "Events & Presentations" in the Investors section of the Company's websit

Xencor to Present at the 2021 Cantor Virtual Global Healthcare Conference

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2021 Results - Earnings Call Transcript

Xencor (XNCR) delivered earnings and revenue surprises of 242.62% and 296.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Q2 Earnings and Revenues Surpass Estimates

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights. “Xencor is applying its leading protein engineering tools and XmAb technology to overcome historical challenges in creating therapeutic mol

Xencor Reports Second Quarter 2021 Financial Results

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021 financial results after the market closes on Wednesday, August 4, 2021. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a cor

Xencor to Host Second Quarter 2021 Financial Results Webcast and Conference Call on August 4, 2021

Xencor (XNCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Xencor (XNCR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Xencor (XNCR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 10.9% in 4 Weeks, Here's Why Xencor (XNCR) Looks Ripe for a Turnaround

Editas Medicine

IGM Biosciences Inc

Ionis Pharma

Zymeworks Inc

These biotech stocks could have great long-term potential.

5 Mid-Cap Healthcare Stocks You'll Want on Your Radar for the 2nd Half of 2021

Xencor (XNCR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Xencor (XNCR) Loses 12.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Acer Therapeutics

Cumberland Pharma

Organogenesis Holdings

4 Small Drug Stocks Set to Escape the COVID-Led Industry Weakness

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present a corporate overview at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 1:00 p.m. ET / 10:00 a.m. PT. A webcast will be available under "Events & Presentati

Xencor to Present at the Jefferies Virtual Healthcare Conference

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for sotrovimab (previously VIR-7831), an XmAb®-engineered antibody developed by Vir Biotechnology, Inc. (Vir) and GlaxoSmithKline plc (GSK). Sotrovimab has not been ap

Sotrovimab (VIR-7831), an Investigational Antibody Utilizing Xencor's Xtend™ Technology, Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

Bristol-Myers

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it has entered into a technology license agreement with Bristol-Myers Squibb Company (NYSE:BMY) under which Bristol Myers Squibb will have non-exclusive access to Xencor's Xtend™ Fc technology to extend the half-life of a novel antibody combination therapy that is i

Xencor and Bristol Myers Squibb Enter License Agreement for Use of Xtend™ XmAb® Technology in SARS-CoV-2 Neutralizing Monoclonal Antibody Combination for the Treatment of COVID-19

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET / 10:20 a.m. PT. A live webcast will be ava

Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference

Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q1 2021 Results - Earnings Call Transcript

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2021 and provided a review of recent business and clinical highlights. "We continue to expand and mature our clinical portfolio of XmAb® drug candidates, recently initiating a Phase 1 study for our second cytoki

Xencor Reports First Quarter 2021 Financial Results

On Wednesday, May 05, Xencor (NASDAQ:XNCR) will release its latest earnings report. Check out Benzinga's preview to understand the implications.

Xencor's Earnings: A Preview

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical study of XmAb564, an engineered IL-2-Fc cytokine in development as a potential treatment for patients with autoimmune diseases. The study will evaluate the safe

Xencor Doses First Subject in Phase 1 Study of XmAb®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2021 financial results after the market closes on Wednesday, May 5, 2021. Xencor management will host a webcast and conference call the same day at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corpora

Xencor to Host First Quarter 2021 Financial Results Webcast and Conference Call on May 5, 2021

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple preclinical XmAb® bispecific antibody programs and its preclinical IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021. "Xencor's XmAb bisp

Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the AACR Annual Meeting 2021

MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on three XmAb® bispecific antibody programs and the IL-12-Fc cytokine program at the American Association for Cancer Research (AACR) Annual Meeting, being held virtually April 10-15, 2021. Abstracts for these poster presentations ar

Xencor to Present Preclinical Data from Four Preclinical XmAb® Bispecific Antibody and Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2021

News for Xencor Stock (XNCR)